Berlex Fellowship Open

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

DUMONT, NJ--The Berlex Oncology Foundation is accepting applications until January 6, 1997, for a 2-year clinical research training program open to academically oriented physicians specializing in oncology. The intent is to encourage careers in clinical cancer research. For more information, contact Svetlana Lisanti, Berlex Oncology Foundation, 80 W. Madison Ave., Dumont, NJ 07628; or call 201-385-0006.

DUMONT, NJ--The Berlex Oncology Foundation is accepting applicationsuntil January 6, 1997, for a 2-year clinical research trainingprogram open to academically oriented physicians specializingin oncology. The intent is to encourage careers in clinical cancerresearch. For more information, contact Svetlana Lisanti, BerlexOncology Foundation, 80 W. Madison Ave., Dumont, NJ 07628; orcall 201-385-0006.

Articles in this issue
Routine Office Endometrial Biopsies and Ultrasound Screening Are Not Recommended for Breast Cancer Patients Receiving Tamoxifen
AHCPR to Fund Analysis of the Impact of Managed Care's Growth
Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Women
ASTRO Honors Two Members With Gold Medal and Bestows Honorary Memberships on Two
Friends of Cancer Research Campaign
Four Cancer Chemoprevention Trials Seek Subjects
Overall US Cancer Mortality Rate Falls for the First Time
Four Scenarios Describe Impact of Cancer Research in 2015
New Edition of NABCO Breast Cancer Resource List Is Now Available
Changes in Congressional Committee Chairmen Could Impact Oncologists
Growth Factor in Elderly ALL Patients Improves Outcome
Human Genetic Map Goes On-Line
Study to Explore Smoking Cessation After a Cancer Diagnosis
Novantrone Gets FDA Nod for Use in Advanced Prostate Cancer
New Cancer Programs, Office of Cancer Survivorship Announced
Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.

Loncastuximab Tesirine Combo Is Effective, Safe in R/R Follicular Lymphoma

April 25th 2024
Article

Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

Cilta-cel Shows High Responses for Lenalidomide-Refractory Myeloma in First Relapse

April 25th 2024
Article

The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.

Eftilagimod Alpha/Pembrolizumab Elicits Encouraging Responses in HNSCC

April 25th 2024
Article

The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

European Commission Approves Enzalutamide in nmHSPC Subset

April 25th 2024
Article

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.